Skip to main content

ANAB

Stock
Health Care
Biotechnology

Performance overview

ANAB Price
Price Chart

Forward-looking statistics

Beta
1.76
Risk
90.75%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Company info

SectorHealth Care
IndustryBiotechnology
Employees109
Market cap$640.1M

Fundamentals

Enterprise value$658.3M
Revenue$111.9M
Revenue per employee
Profit margin-125.70%
Debt to equity1016.89

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.76
Dividend per share
Revenue per share$3.81
Avg trading volume (30 day)$15M
Avg trading volume (10 day)$10M
Put-call ratio

Macro factor sensitivity

Growth-0.7
Credit+5.1
Liquidity+0.1
Inflation-3.5
Commodities-1.5
Interest Rates-0.7

Valuation

Dividend yield0.00%
PEG Ratio-3.71
Price to sales6.24
P/E Ratio-3.71
Enterprise Value to Revenue5.88
Price to book21.21

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

AnaptysBio, Inc. ANAB on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.

Benzinga (June 4, 2025)
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1.64 per share a year ago.

Zacks Investment Research (May 5, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free